You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1392-ESGO Tisotumab vedotin combinations with pembrolizumab or carboplatin in patients with recurrent/metastatic cervical cancer: interim results of ENGOT Cx8/GOG-3024/innovaTV205

Citation Tools

Article menu

Download PDFPDF

Cervical cancer
2022-RA-1392-ESGO Tisotumab vedotin combinations with pembrolizumab or carboplatin in patients with recurrent/metastatic cervical cancer: interim results of ENGOT Cx8/GOG-3024/innovaTV205
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Lorusso D, Vergote I, O’Cearbhaill RE, et al
2022-RA-1392-ESGO Tisotumab vedotin combinations with pembrolizumab or carboplatin in patients with recurrent/metastatic cervical cancer: interim results of ENGOT Cx8/GOG-3024/innovaTV205
International Journal of Gynecologic Cancer 2022;32:A57-A58.